IVERIC bio, Inc. Profile Avatar - Palmy Investing

IVERIC bio, Inc.

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 compri…
Biotechnology
US, Parsippany [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
IVERIC bio, Inc. can't present any analysts estimates at the moment detail analysis.
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
IVERIC bio, Inc. can't present the grade consensus distribution right now.
Price Target Consensus
Price Then
$n/a
Price Target
$n/a
Price Now
$39.95
End of ISEE's Analysis
CIK: 1410939 CUSIP: 46583P102 ISIN: US46583P1021 LEI: - UEI: -
Secondary Listings
ISEE has no secondary listings inside our databases.